Avenue Therapeutics (ATXI) Institutional Ownership $0.36 +0.01 (+2.83%) As of 10:35 AM Eastern Add Compare Share Share Ownership Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Avenue Therapeutics (NASDAQ:ATXI)CurrentInstitutional OwnershipPercentage17.34%Number ofInstitutional Buyers(last 12 months)3TotalInstitutional Inflows(last 12 months)$372.07KNumber ofInstitutional Sellers(last 12 months)0 Get ATXI Insider Trade Alerts Want to know when executives and insiders are buying or selling Avenue Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data ATXI Institutional Buying and Selling by Quarter Avenue Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/14/2025Boothbay Fund Management LLC41,089$82K0.0%N/A2.004% 10/18/2024Moss Adams Wealth Advisors LLC11,000$27K0.0%N/A1.169% 8/15/2024Armistice Capital LLC75,000$262K0.0%N/A7.970% 1/28/2022National Asset Management Inc.71,338$65K0.0%-20.1%0.376% 11/16/2021National Asset Management Inc.89,237$133K0.0%-29.2%0.531% 10/19/2021Kestra Advisory Services LLC22,500$34K0.0%N/A0.134% 9/17/2021Virtu Financial LLC26,373$66K0.0%N/A0.157% 9/3/2021Parametric Portfolio Associates LLC10,554$26K0.0%-59.2%0.063% 8/16/2021Occudo Quantitative Strategies LP14,398$36K0.0%N/A0.086% 8/13/2021Renaissance Technologies LLC78,314$197K0.0%N/A0.468% 8/13/2021Northern Trust Corp13,767$35K0.0%-82.1%0.082% 8/13/2021Geode Capital Management LLC79,556$199K0.0%-40.0%0.475% 8/13/2021Vanguard Group Inc.449,982$1.13M0.0%-35.5%2.687% 8/12/2021XTX Topco Ltd10,864$27K0.0%N/A0.065% 8/12/2021Advisory Services Network LLC35,121$88K0.0%N/A0.210% 8/12/2021Ergoteles LLC30,400$76K0.0%N/A0.182% 8/10/2021National Asset Management Inc.126,037$317K0.0%-26.1%0.753% 5/20/2021Axiom Investment Management LLC10,000$60K0.0%N/A0.060% 5/19/2021Squarepoint Ops LLC11,668$71K0.0%N/A0.070% 5/17/2021Goldman Sachs Group Inc.17,319$105K0.0%N/A0.103% 5/13/2021Barclays PLC5,568$34K0.0%+159.0%0.033% 5/12/2021Northern Trust Corp77,049$467K0.0%-6.8%0.460% 5/12/2021Geode Capital Management LLC132,594$804K0.0%+5.9%0.792% (Data available from 1/1/2016 forward) ATXI Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ATXI shares? During the previous two years, the following institutional investors and hedge funds held shares of Avenue Therapeutics shares: Armistice Capital LLC ($262K), and Boothbay Fund Management LLC ($82K), Moss Adams Wealth Advisors LLC ($27K).Learn more on Avenue Therapeutics' institutional investors. What percentage of Avenue Therapeutics' stock is owned by institutional investors? 17.34% of Avenue Therapeutics' stock is owned by institutional investors. Learn more on ATXI's institutional investor holdings. Which institutional investors have been buying Avenue Therapeutics' stock? The following institutional investors have purchased Avenue Therapeutics' stock in the last 24 months: Armistice Capital LLC ($75K), Boothbay Fund Management LLC ($41.09K), and Moss Adams Wealth Advisors LLC ($11K). How much institutional buying is happening at Avenue Therapeutics? Institutional investors have bought a total of 127,089 shares in the last 24 months. This purchase volume represents approximately $372.07K in transactions. Related Companies Matinas Biopharma Major Shareholders Redhill Biopharma Major Shareholders CNS Pharmaceuticals Major Shareholders Dermata Therapeutics Major Shareholders Tharimmune Major Shareholders Soligenix Major Shareholders Spruce Biosciences Major Shareholders Clearmind Medicine Major Shareholders SciSparc Major Shareholders Virax Biolabs Group Major Shareholders This page (NASDAQ:ATXI) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get Paid“I’ve always hated gold. It doesn’t pay dividends… it just sits there.” That’s what one income strategist b...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avenue Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avenue Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
